• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.710 -0.050 (-2.84%)
Official Closing Price Updated: 8:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,001,484
Open 1.770
Bid (Size) 1.700 (500)
Ask (Size) 1.750 (700)
Prev. Close 1.760
Today's Range 1.690 - 1.770
52wk Range 0.3651 - 2.090
Shares Outstanding 174,986,671
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
January 06, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Issues Letter to Stockholders
January 05, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire

Performance

YTD
+4.3%
+4.3%
1 Month
-1.7%
-1.7%
3 Month
+3.0%
+3.0%
6 Month
+66.0%
+66.0%
1 Year
+194.8%
+194.8%

More News

Read More
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
August 11, 2025
Via Benzinga
News headline image
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
November 06, 2025
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
October 30, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
September 22, 2025
Via Benzinga
News headline image
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
September 08, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
August 27, 2025
Via Benzinga
News headline image
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
September 02, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
August 26, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
August 15, 2025
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
August 12, 2025
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
August 12, 2025
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
August 12, 2025
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
August 05, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
June 23, 2025
Via Benzinga
News headline image
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
June 05, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
August 04, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
May 14, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
June 23, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 13, 2025 ↗
May 13, 2025
Via Benzinga

Frequently Asked Questions

Is Lineage Cell Therapeutics, Inc. Common Stock publicly traded?
Yes, Lineage Cell Therapeutics, Inc. Common Stock is publicly traded.
What exchange does Lineage Cell Therapeutics, Inc. Common Stock trade on?
Lineage Cell Therapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock?
The ticker symbol for Lineage Cell Therapeutics, Inc. Common Stock is LCTX on the New York Stock Exchange
What is the current price of Lineage Cell Therapeutics, Inc. Common Stock?
The current price of Lineage Cell Therapeutics, Inc. Common Stock is 1.710
When was Lineage Cell Therapeutics, Inc. Common Stock last traded?
The last trade of Lineage Cell Therapeutics, Inc. Common Stock was at 01/09/26 08:00 PM ET
What is the market capitalization of Lineage Cell Therapeutics, Inc. Common Stock?
The market capitalization of Lineage Cell Therapeutics, Inc. Common Stock is 299.23M
How many shares of Lineage Cell Therapeutics, Inc. Common Stock are outstanding?
Lineage Cell Therapeutics, Inc. Common Stock has 299M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap